Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02239289
Other study ID # FIR UQTR 2013-2014
Secondary ID
Status Completed
Phase N/A
First received September 4, 2014
Last updated July 10, 2015
Start date March 2014
Est. completion date November 2014

Study information

Verified date July 2015
Source Université du Québec à Trois-Rivières
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

The purpose of the present study is to evaluate the benefit of biofeedback training on the capacity of chronic low back pain patients to decrease their lumbar paraspinal muscles activity during trunk full flexion and its relationship with changes in clinical outcomes. To do so, twenty patients with nonspecific mechanical low back pain will be recruited and all participants will take part in four sessions of supervised biofeedback training, consisting of 5 blocks with at least 12 trunk flexion-extension tasks. It is hypothesized that participants will have improved neuromechanical parameters with the biofeedback training and that this improvement will be positively associated to changes in clinical outcomes. This study will also allow for generation of preliminary data, in order to plan for a larger randomized control trial.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date November 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Being between 18 and 60 years of age.

- Presence of non-specific chronic low back pain.

Exclusion Criteria:

- Prior surgery or major spine trauma.

- Lumbar scoliosis greater than 20°.

- Neuromuscular disease.

- Malignant tumor.

- Uncontrolled hypertension.

- Infection.

- Neurological deficit.

- Symptomatic lumbar disc herniation.

- Pregnancy.

- Recent lumbar cortisone injection.

- Active lower body injury and/or disabling pain limiting the capacity to complete the experimentation.

- Being under medications known to impair physical effort and pain perception.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Other:
Biofeedback
Idem as described in the arm section (above)

Locations

Country Name City State
Canada Université du Québec à Trois-Rivières Trois-Rivières Quebec

Sponsors (1)

Lead Sponsor Collaborator
Université du Québec à Trois-Rivières

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Demoulin C, Crielaard JM, Vanderthommen M. Spinal muscle evaluation in healthy individuals and low-back-pain patients: a literature review. Joint Bone Spine. 2007 Jan;74(1):9-13. Epub 2006 Nov 13. Review. — View Citation

Frank DL, Khorshid L, Kiffer JF, Moravec CS, McKee MG. Biofeedback in medicine: who, when, why and how? Ment Health Fam Med. 2010 Jun;7(2):85-91. — View Citation

Giggins OM, Persson UM, Caulfield B. Biofeedback in rehabilitation. J Neuroeng Rehabil. 2013 Jun 18;10:60. doi: 10.1186/1743-0003-10-60. Review. — View Citation

Hodges PW. Pain and motor control: From the laboratory to rehabilitation. J Electromyogr Kinesiol. 2011 Apr;21(2):220-8. doi: 10.1016/j.jelekin.2011.01.002. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Flexion-relaxation Ratio Flexion-relaxation ratio is calculated by dividing muscle activity (EMG) during trunk flexion by muscle activity during full-flexed position. EMG of lumbar paraspinal muscles is recorder through surface EMG during every trials of each session. Week 1 No
Primary Flexion-relaxation Ratio Flexion-relaxation ratio is calculated by dividing muscle activity (EMG) during trunk flexion by muscle activity during full-flexed position. EMG of lumbar paraspinal muscles is recorder through surface EMG during every trials of each session. Week 2 No
Primary Flexion-relaxation Ratio Flexion-relaxation ratio is calculated by dividing muscle activity (EMG) during trunk flexion by muscle activity during full-flexed position. EMG of lumbar paraspinal muscles is recorder through surface EMG during every trials of each session. Week 3 No
Primary Flexion-relaxation Ratio Flexion-relaxation ratio is calculated by dividing muscle activity (EMG) during trunk flexion by muscle activity during full-flexed position. EMG of lumbar paraspinal muscles is recorder through surface EMG during every trials of each session. Week 4 No
Secondary Lumbo-pelvic Range of Motion During Trunk Flexion-extension Range of motion is recorder throught 8 kinematic markers placed on the right lower limb and the back of each participant during every trials of each session. Week 1 No
Secondary Disability Level Oswestry disability index ranges from 0 to 100. A higher score indicates higher disability. Week 4 No
Secondary Pain Intensity in the Past Week 101-points numerical rating scale that ranges from 0 (no pain) to 100 (worst possible pain). Week 2 No
Secondary Current Pain Intensity 101-points numerical rating scale that ranges from 0 (no pain) to 100 (worst possible pain). Week 3 No
Secondary Fear of Movement Level Tampa scale for kinesiophobia ranges from 0 to 68. Higher score indicates higher fear of movement level. Week 4 No
Secondary Current Pain Intensity 101-points numerical rating scale that ranges from 0 (no pain) to 100 (worst possible pain). Week 2 No
Secondary Current Pain Intensity 101-points numerical rating scale that ranges from 0 (no pain) to 100 (worst possible pain). Week 4 No
Secondary Pain Intensity in the Past Week 101-points numerical rating scale that ranges from 0 (no pain) to 100 (worst possible pain). Week 3 No
Secondary Pain Intensity in the Past Week 101-points numerical rating scale that ranges from 0 (no pain) to 100 (worst possible pain). Week 4 No
Secondary Lumbo-pelvic Range of Motion During Trunk Flexion-extension Range of motion is recorder throught 8 kinematic markers placed on the right lower limb and the back of each participant during every trials of each session. Week 2 No
Secondary Lumbo-pelvic Range of Motion During Trunk Flexion-extension Range of motion is recorder throught 8 kinematic markers placed on the right lower limb and the back of each participant during every trials of each session. Week 3 No
Secondary Lumbo-pelvic Range of Motion During Trunk Flexion-extension Range of motion is recorder throught 8 kinematic markers placed on the right lower limb and the back of each participant during every trials of each session. Week 4 No
See also
  Status Clinical Trial Phase
Completed NCT03243084 - Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy N/A
Suspended NCT04735185 - Stem Cells vs. Steroids for Discogenic Back Pain N/A
Completed NCT03162952 - RAND Center of Excellence for the Study of Appropriateness of Care in CAM
Completed NCT03240146 - Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain N/A
Completed NCT05282589 - Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients N/A
Completed NCT03637998 - Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain N/A
Recruiting NCT02289170 - Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) N/A
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT02231554 - Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial N/A
Recruiting NCT02063503 - Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients N/A
Completed NCT01704677 - Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT01490905 - A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain Phase 4
Completed NCT01177241 - Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids N/A
Completed NCT01177280 - Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes N/A
Completed NCT01177254 - Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions N/A
Completed NCT00984815 - Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Phase 3
Completed NCT00767806 - A Study for Patient With Chronic Low Back Pain Phase 3
Completed NCT00761150 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00763321 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3